Article Text

PDF
Henoch-Schönlein purpura and meningococcal B vaccination
  1. K Sexton1,
  2. A McNicholas1,
  3. Y Galloway1,
  4. S Radke1,
  5. C Kieft1,
  6. P Stehr-Green1,
  7. S Reid1,
  8. J Neutze2,
  9. R Drake3
  1. 1
    Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
  2. 2
    Middlemore Hospital, Manukau, New Zealand
  3. 3
    Auckland City Hospital, Auckland, New Zealand
  1. Anne McNicholas, Meningococcal Vaccine Strategy, Ministry of Health, PO Box 5013, Wellington, New Zealand; anne_mcnicholas{at}moh.govt.nz

Abstract

The risk of Henoch-Schönlein purpura (HSP) following vaccination with a group B meningococcal vaccine was assessed through active hospital safety monitoring. There was no increase in the relative incidence of HSP within 30 days after vaccination nor recurrence in HSP cases who received one or more further vaccine doses (re-challenge).

Statistics from Altmetric.com

Footnotes

  • Competing interests: Chiron Vaccines (now Novartis Vaccines and Diagnostics S.r.l.) funded the New Zealand Ministry of Health to undertake the safety monitoring.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.